IVST 0.4200 (-12.5000%)
Innovest Global, Inc on Twitter Innovest Global, Inc on Facebook Innovest Global, Inc on Instagram Innovest Global, Inc on LinkedIn

Innovest Global Inc. to Launch Biotech and Health Sciences Division Led by World Renowned Neuroscientist, Dr. Dwain Morris-Irvin

View at GlobeNewswire.com

CLEVELAND, March 05, 2018 (GLOBE NEWSWIRE) -- Innovest Global Inc. (OTC PINK:IVST) is pleased to announce that it has tapped Dr. Dwain Morris-Irvin, PhD MPH, to launch a Biotechnology and Health Sciences division for Innovest this spring, to be headquartered in Los Angeles, CA. The division expects to have ownership in technologies that have the potential to be significantly valuable.

With this development to its diversified model, Innovest has defined its second industry focus: Biotechnology and Health Sciences. Innovest will now have a beachhead from which they can accumulate interests in up-and-coming biotech and health science intellectual property, patents, and initiatives; and generate revenue from associated activities. This division adds a second leg to operations that are currently focused on reliable revenue streams from a commercial and industrial client base in the areas of energy, and durable goods.

Dr. Morris-Irvin is an active participant in many Biotechnology and Health Science endeavors, and is an expert including patent generation in such areas as treatments for Parkinson’s, brain cancer, and even cosmetic application of advanced bioscience. He is also an expert in the physical operations of laboratories, and hospitals. He received his PhD from UCLA School of Medicine, and Masters in Public Health from UCLA School of Public Health, and trained at The Wallenberg Neuroscience Center at Lund University in Lund, Sweden. He was also a Professor, Faculty member at Cedars-Sinai Medical Center, Department of Neurosurgery.

Dr. Morris-Irvin has significant enthusiasm for this effort, “Dan Martin (CEO of Innovest) has a demonstrated history of adding business value to Health Science organizations I have led in the past, that have resulted in improved quality of life for people. His proven commitment to scientific advancement and his ability to execute in business, are why I am so excited about the potential we have to use the well-structured Innovest model, to create significant value. Value not only for Innovest shareholders; but for the public interest at large and the scientists and organizations behind general health and biotechnology initiatives around the world.”

“Dr. Morris-Irvin has a unique combination of subject matter expertise, experience, and business acumen that make him a perfect leader for this division,” said Innovest CEO, Dan Martin. “And he’s one of the most respected professionals and best people you could ever have the pleasure to know. We expect this division to result in ownership of meaningful intellectual property and other progress, without the significant capital costs of traditional biotech initiatives. His relationships, plans, and creativity tell me we will have an exiting path ahead that we are well equipped to execute, and I am thrilled to get started on it with him at the helm.”

More about Dr. Morris-Irvin:

Dr. Morris-Irvin’s PhD is in Pharmacology and Developmental Neuroscience with an emphasis on neural stem cell fate and differentiation. His research focused on neural development and Notch Signaling in mammalian neural stem cells. He also worked as an NIH/NINDS Post-Doctoral Fellow in Dr. Anders Bjorklund laboratory in Lund, Sweden. There, his focus was on research projects that investigated the potential role of cell replacement therapy for patients with Parkinson’s disease. They developed several protocols for the efficient generation of dopaminergic neurons from forebrain and ventral midbrain stem and progenitor cells.

Additionally, Dr. Morris-Irvin led research investigations in the role of adaptive immunity in Parkinson’s disease. He also developed two patents in the area of immunotherapy for brain tumor patients, specifically Glioblastoma Multiforme (GBM). His research team focused on molecular mechanisms that impart therapeutic resistance in cancer cells, including cancer stem cells. They utilized this data to develop novel immunotherapies for brain tumor patients.

Look for much more information to come soon. As noted consistently, the company will increasingly use Twitter, which can be accessed both on Twitter @innovestglobal and on the front page of our website www.innovestglobal.com, for important company updates. This includes information that may be material, so please follow us and visit our website regularly! For more information on Innovest contact info@innovestglobal.com, or call Innovest investor Relations Matt Rego at 216.815.1122.

http://www.innovestglobal.com 

Safe Harbor Statement: This news release contains "forward-looking statements", which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. 

For more information on Innovest Investor Relations, Spotlight Growth, please visit http://www.SpotlightGrowth.com and http://www.Corporate.SpotlightGrowth.com.

You can also follow on social media:
Innovest Twitter: https://twitter.com/InnovestGlobal
Spotlight Growth Twitter: https://twitter.com/SpotlightGrowth
Spotlight Growth Facebook: https://facebook.com/Spotlight-Growth-103630363712364/
Spotlight Growth LinkedIn: https://www.linkedin.com/in/spotlight-growth-732ba1147
Spotlight Growth Instagram: https://www.instagram.com/spotlight_growth/

Contact Information
Corporate Office:
(216) 815-1122
info@innovestglobal.com
Twitter @innovestglobal

Investor Relations:
Hayden IR
(917) 658-7878
hart@haydenir.com